NASDAQ: TENX
TENAX THERAPEUTICS, INC.CIK 0000034956 · Pharmaceutical Preparations
Each report below shows a 3-bullet preview. Free accounts read 3 full reports a month — narrative summary, section diffs, and EDGAR-cited quotes.
Sign up freeWant to see a complete report first? Today's free report (ISNR 10-Q) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade TENX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Summary not yet generated.
Tenax Therapeutics holds routine annual meeting, elects seven directors for one-year terms
2 material changes detected. Sign up free to read the summary.
Tenax Therapeutics reports Q1 2026 financial results
2 material changes detected. Sign up free to read the summary.
TENX completes Phase 3 trial enrollment, extends cash runway to Q1 2028 on warrant proceeds
5 material changes detected. Sign up free to read the summary.
Tenax Therapeutics appoints Thomas R. Staab as CFO with $428K salary, 450K stock options
4 material changes detected. Sign up free to read the summary.
Tenax completes Phase 3 enrollment, raises $125M, extends runway to end-2027
5 material changes detected. Sign up free to read the summary.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-Q filed May 12, 2026 (period ending Mar 31, 2026). SEC XBRL (companyfacts) — not generated by the model.
Consolidated Statements of Operations (Unaudited)
| Description | Q1 ended Mar 31, 2026 | Q1 ended Mar 31, 2025 |
|---|---|---|
| Revenue: | ||
| Total revenue / net sales | — | — |
| Operating expenses: | ||
| Research and development | 11.5 | 5.7 |
| General and administrative | 5.0 | 5.7 |
| Total operating expenses | 16.6 | 11.3 |
| Operating income | (16.6) | (11.3) |
| Other income/(expense), net | — | — |
| Net income | (15.7) | (10.4) |
| Basic earnings per share | (0.35) | (0.28) |
| Diluted earnings per share | (0.35) | (0.28) |
Consolidated Balance Sheets (Unaudited)
| Description | Mar 31, 2026 | Mar 31, 2025 |
|---|---|---|
| Current assets: | ||
| Cash and equivalents | 118.8 | 111.4 |
| Prepaid expenses and other current assets | 0.1 | 0.09 |
| Other current assets | 4.3 | 0.6 |
| Total current assets | 123.2 | 112.1 |
| TOTAL ASSETS | 123.2 | 112.1 |
| Current liabilities: | ||
| Accounts payable | 6.3 | 1.8 |
| Accrued liabilities | 2.1 | 0.9 |
| Total current liabilities | 8.5 | 2.8 |
| Total liabilities | 8.5 | 2.8 |
| Shareholders' equity: | ||
| Common stock | — | — |
| Capital in excess of stated value | 497.9 | 434.6 |
| Retained earnings (deficit) | (383.2) | (325.3) |
| Total shareholders' equity | 114.7 | 109.3 |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | 123.2 | 112.1 |
Consolidated Statements of Cash Flows (Unaudited)
| Description | Q1 ended Mar 31, 2026 | Q1 ended Mar 31, 2025 |
|---|---|---|
| Operating Activities: | ||
| Net cash from operating activities | (9.3) | (7.0) |
| Investing Activities: | ||
| Net cash from investing activities | — | |
| Financing Activities: | ||
| Net cash from financing activities | 30.5 | 23.6 |
Amounts in millions USD; EPS as reported. Line labels are presentation-friendly mappings of filer XBRL tags — not a re-audit of the full statements. Use EDGAR for interactive notes and detail. Interactive statements & notes on EDGAR ↗